Decera Clinical Education Oncology Podcast

In this podcast episode, Toby A. Eyre, MD, MBChB, and Tycel J. Phillips, MD, FASCO, discuss the evolving treatment landscape of R/R mantle cell lymphoma as covalent BTK inhibitor use further expands into the first-line setting. They highlight the similarities and differences between small molecules pirtobrutinib and sonrotoclax including patient selection, step-up dosing requirements, TLS monitoring, efficacy post covalent BTKi, sequencing, and the feasibility of implementing treatment in community practices. They also examine the dosing, efficacy, and safety of CAR T-cell therapy and bispecific antibodies, establishing their current and possible future roles in R/R MCL.Presenters:Toby A. Eyre, MD, MBChBHematology ConsultantDepartment of HematologyOxford University Hospitals NHS TrustOxford, United KingdomTycel J. Phillips, MD, FASCOAssociate Professor of MedicineCity of Hope National Medical CenterDuarte, CaliforniaLink to full program: https://bit.ly/4k7VkrvGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This podcast explores the evolving treatment landscape for marginal zone lymphoma (MZL), focusing on individualized treatment selection, emerging cellular therapies, and novel T-cell–engaging approaches for relapsed/refractory disease. Examine evidence supporting current treatment options, including BTK inhibitors and CAR T-cell therapy, as well as emerging clinical data on CD20 x CD3 bispecific antibodies such as odronextamab and mosunetuzumab. The discussion also addresses clinical trial referral, patient eligibility, and practical strategies for monitoring and managing treatment-related toxicities.Presenters:Dai Chihara, MD, PhDAssociate ProfessorDepartment of Lymphoma and MyelomaUniversity of Texas MD Anderson Cancer CenterHouston, TexasJ.C. Villasboas B., MDAssistant Professor of Medicine and OncologyMayo Clinic College of MedicineConsultant, Division of Hematology, Lymphoma/Bone Marrow Transplant/Cellular Therapy GroupsDirector, Mayo Clinic Immune Monitoring Core LaboratoryRochester, MinnesotaLink to the full program:https://bit.ly/4zw8VOqGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Christine M. Bestvina, MD, and Joshua E. Reuss, MD, discuss the current and emerging role of TROP2-directed ADCs in NSCLC, including:Current clinical use of Dato-DXd in previously treated EGFR-mutated NSCLC, including evidence from TROPION-Lung01 and TROPION-Lung05 and considerations for treatment sequencingEmerging efficacy data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and the potential role of these agents in earlier lines of therapyOngoing clinical trials evaluating TROP2 ADCs alone and in combination with immunotherapy, chemotherapy, or EGFR-targeted therapies, including TROPION-Lung07, TROPION-Lung08, TROPION-Lung14, TROPION-Lung15, and AVANZARBiomarker-guided patient selection, including the potential of the TROP2 QCS-NMR biomarker to identify patients most likely to benefit from Dato-DXdSafety and supportive care considerations, including prevention and management of stomatitis, ocular toxicities, and interstitial lung disease/pneumonitisGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.Presenters:Christine M. Bestvina, MDAssociate Professor of MedicineSection of Hematology/OncologyDivision of MedicineUniversity of Chicago MedicineChicago, IllinoisJoshua E. Reuss, MDThoracic Medical OncologistDirector of Thoracic Clinical ResearchAssociate Professor of MedicineGeorgetown Lombardi Comprehensive Cancer CenterWashington, DCLink to full program: https://bit.ly/4iumiap Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss evolving therapy in newly diagnosed multiple myeloma, including:Selecting quadruplet therapyOptimal use of bortezomibThe role of autologous stem cell transplantation in the quadruplet eraUse of MRD status to inform treatment decisionsMaintenance strategies Presenters:Jesus G. Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for Research PartnerTennessee OncologyNashville, TennesseeAjai Chari, MDProfessor of Clinical MedicineDirector of Multiple Myeloma ProgramUCSF Helen Diller Family Comprehensive Cancer CenterUniversity of California, San Francisco (UCSF) Medical CenterSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from GSK.Link to full program: https://bit.ly/4yTeLZDGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify appropriate patients for PARP-directed therapy and proactive adverse event management to support treatment continuation, including:HRR alterations and the mechanism of action of PARP inhibitorsGermline and somatic genomic testing and practical considerations for tissue and ctDNA testingPARP inhibitor monotherapy and combination strategies, including data from AMPLITUDE and TALAPRO-3Treatment selection across metastatic prostate cancer settings based on HRR alterationsPARP inhibitor toxicity management, with emphasis on anemia, gastrointestinal effects, monitoring, and dose modificationPresenters:Neeraj Agarwal, MD, FASCOMedical Oncologist, Dana-Farber Cancer InstituteCo-Director, Prostate Cancer Program, Harvard Cancer ConsortiumThe Lank Center for Genitourinary OncologyBoston, MassachusettsEmmanuel S. Antonarakis, MDClark Endowed Professor of MedicineDirector of GU Oncology, Associate Director of TranslationDivision of Hematology, Oncology and TransplantationUniversity of Minnesota, Masonic Cancer CenterMinneapolis, MinnesotaLink to full program: https://bit.ly/4dtT35UGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.